Reirradiation and Erbitux in the HNSCC
NCT01237483 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2017-10-26
Summary
The purpose of this study is to investigate in patients with cancer of the throat and recurrent inoperable a different modality treatment consisting of radiation continuously for 5 weeks and half associated with a drug directed against a receptor on cell surfaces cancer, called Erbitux ®.
The investigators hope with this shorter treatment (1.5 weeks less than the usual treatment) to improve the antitumor efficacy without additional toxic side effects.
Conditions
- Head and Neck Cancer Squamous Cell
Interventions
- DRUG
-
To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
Sponsors & Collaborators
-
Groupe Oncologie Radiotherapie Tete et Cou
lead OTHER
Principal Investigators
-
Laurent MARTIN, oncologist · Centre Guillaume Le Conquérant, 76600 Le Havre, France
-
Claude TUCHAIS, oncologist · Centre Paul Papin, 49933 Angers, France
-
Sauveur Marc ALFONSI, oncologist · Institut Sainte Catherine, 84082 Avignon, France
-
Xu Sh SUN, oncologist · Hôpital Jean Minoz, 25030 Besançon, France
-
Dominique DE RAUCOURT, oncologist · Centre François Baclesse, 14076 Caen, France
-
Michel LAPEYRE, oncologist · Centre Jean Perrin, 63011 Clermond-Ferrand, France
-
Philippe MAINGON, oncologist · Centre G-F Leclerc, 21079 Dijon, France
-
Muriel GARCIA-RAMIREZ, oncologist · Hôpital Robert Boulin, 33505 Libourne, France
-
Christian SIRE, oncologist · Hôpital du Scorff, 56322 Lorient, France
-
Séverine RACADOT, oncologist · Centre Léon Bérard, 69373 Lyon, France
-
Véronique FAVREL, oncologist · Centre Hospitalier Lyon Sud, 69495 Pierre-Benite, France
-
Etienne BARDET, oncologist · Centre René Gauducheau, 44805 Nantes-St Herblain, France
-
Philippe LANG, oncologist · Hôpital de La Pitié Salpitrière, 75013 Paris, France
-
Isabelle TENNEVET, oncologist · Centre Henri Becquerel, 76038 Rouen, France
-
Patricia BURBAN, oncologist · Clinique Armoricaine de Radiologie, 22015 St Brieuc, France
-
Olivier GALLOCHER, oncologist · Clinique Pasteur, 31300 Toulouse, France
-
Olivier GALLOCHER, oncologist · Polyclinique du Parc, 31078 Toulouse, France
-
Yungan TAO, oncologist · Institut Gustave Roussy, 94805 Villejuif, France
-
Pierre BOISSELIER, oncologist · Val d'Aurelle 34298 Montpellier cedex
-
Frédéric PEYRADE, oncologist · Centre Antoine Lacassagne 06189 NICE cedex 2
-
Marie SALIOU, oncologist · Clinique de l' Estuaire 44600 Pornichet
-
Cédrik LAFOND, oncologist · Centre Jean Bernard 72000 Le Mans
-
René-Jean BENSADOUN, oncologist · CHU 86021 Poitiers cedex
-
Alexandre COUTTE, oncologist · CHU Amiens sud 80004 Amiens
-
Hao QIU, oncologist · CHU 86000 Limoges
-
Florence HUGUET, oncologist · Hôpital Tenon 75020 Paris
-
Sébastien GUIHARD · Centre Paul Strauss 67065 Strasbourg
-
Xu Shan SUN, oncologist · Centre Hospitalier de Belfort Montbéliard Bd du Maréchal Juin 25200 Montbéliard
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2016-07-31
- Completion
- 2016-07-05
Countries
- France
Study Locations
More Related Trials
-
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01218048 ·Status: COMPLETED ·Phase: PHASE2
-
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
NCT00570674 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
NCT04834349 ·Status: WITHDRAWN ·Phase: PHASE2
-
Simultaneous Integrated Boost (SIB)- IMRT
NCT00389727 ·Status: COMPLETED ·Phase: PHASE2
-
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
NCT01084083 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
NCT00468169 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy and Safety of Local Cryotherapy Treatment of Recurrent Head and Neck Cancer in Irradiated Areas: a Pilot Study
NCT05738187 ·Status: RECRUITING ·Phase: NA
-
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC
NCT02707588 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
NCT00738868 ·Status: COMPLETED ·Phase: PHASE2
-
Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours
NCT03238378 ·Status: RECRUITING ·Phase: NA
-
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
NCT01553032 ·Status: COMPLETED ·Phase: PHASE4
-
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
NCT06640725 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
NCT02388932 ·Status: TERMINATED ·Phase: NA
-
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
NCT02938273 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
NCT04474470 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer
NCT03892720 ·Status: COMPLETED ·Phase: NA
-
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
NCT04576091 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
NCT00934518 ·Status: WITHDRAWN ·Phase: PHASE2
-
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
NCT00713219 ·Status: COMPLETED ·Phase: PHASE2
-
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
NCT01935921 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
NCT00903461 ·Status: TERMINATED ·Phase: PHASE1
-
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
NCT00343083 ·Status: COMPLETED ·Phase: PHASE2
-
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
NCT05047094 ·Status: RECRUITING ·Phase: NA
-
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
NCT00122460 ·Status: COMPLETED ·Phase: PHASE3
-
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
NCT00251381 ·Status: UNKNOWN ·Phase: PHASE2